Raises FY25 revenue view to $768M-$793M from $756M-$776M, consensus $769.64M. Sees FY25 adjusted EBITDA $195M-$205M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Files Proxy for 2025 Meeting
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals presents preclinical data on use of Cortrophin Gel
- ANI Pharmaceuticals: Strategic Shift and Litigation Outcomes Poised to Drive Growth
- ANI Pharmaceuticals price target raised to $65 from $62 at Truist